A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

PHASE3CompletedINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

May 16, 2017

Primary Completion Date

August 13, 2018

Study Completion Date

January 9, 2019

Conditions
Psoriasis
Interventions
DRUG

Apremilast

Apremilast 30 mg tablets BID from weeks 0 to 32.

OTHER

Placebo

Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.

Trial Locations (45)

10029

Icahn School of Medicine at Mount Sinai Medical Center, New York

10075

Sadick Research Group, New York

11203

SUNY Downstate Medical Center, Brooklyn

11375

Forest Hills Dermatology Group, Forest Hills

15213

University of Pittsburgh Medical Center, Pittsburgh

20850

Lawrence Green, MD, LLC, Rockville

23502

Virginia Clinical Research Inc, Norfolk

23507

Eastern Virginia Medical School, Norfolk

27104

Wake Forest University Health Sciences, Winston-Salem

30263

MedaPhase INC, Newnan

31217

Dermatologic Surgery Specialists, P.C., Macon

33134

Florida Academic Centers Research and Education, Coral Gables

33144

International Dermatology Research, Miami

34470

Renstar Medical Research, Ocala

40202

DS Research, Louisville

40241

DS Research, Louisville

45324

Wright State Physicians, Fairborn

46168

The Indiana Clinical Trials Center, PC, Plainfield

53226

Medical College of Wisconsin, Milwaukee

63117

Central Dermatology, St Louis

68144

Skin Specialists, PC, Omaha

70605

Dermatology and Advanced Aesthetics, Lake Charles

72758

Northwest Arkansas Clinical Trials Center, PLLC / Hull Dermatology, Rogers

75231

Modern Research Associates PLLC, Dallas

77598

Center for Clinical Studies, Webster

78705

Austin Dermatology Associates, Austin

84107

University of Utah, Salt Lake City

90045

Dermatology Research Associates, Los Angeles

92708

Tien Q. Nguyen MD Inc, Fountain Valley

93405

San Luis Dermatology and Laser Clinic, San Luis Obispo

06030

University of Connecticut, Farmington

08520

Psoriasis Treatment Center of Central New Jersey, East Windsor

T2G 1B1

Kirk Barber Research, Calgary

T3A 2N1

Institute for Skin Advancement, Calgary

V3R 6A7

Chih-Ho Hong Medical, Inc., Surrey

V3V 0C6

Enverus Medical Research, Surrey

R3M 3Z4

Wiseman Dermatology Research Inc., Winnipeg

L3P1X2

Lynderm Research, Markham

P1B 3Z7

North Bay Dermatology Center, North Bay

K9J 5K2

Skin Center for Dermatology, Peterborough

L4B 1A5

Centre For Dermatology and Cosmetic Surgery, Richmond Hill

M3H 5Y8

The Toronto Dermatology Centre, Toronto

N2J 1C4

K. Papp Clinical Research, Waterloo

N8W 1E6

XLR8 Medical Research, Windsor

G1V 4X7

Centre de Recherche Dermatologique du Quebec Metropolitain CRDQ, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03123471 - A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp | Biotech Hunter | Biotech Hunter